SCHEMBL19319682

SCHEMBL19319682

CCc1ccc(Oc2c[nH]nc2-c2ccc(OCCc3ccc(F)cc3)cc2O)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 11/20 0.43
KMT2A Q03164 9/20 0.43
MEN1 O00255 8/20 0.43
MAPK1 P28482 7/20 0.43
NPSR1 Q6W5P4 7/20 0.43
ALOX12 P18054 5/20 0.43
USP2 O75604 4/20 0.43
LMNA P02545 4/20 0.43
HTT P42858 4/20 0.43
XBP1 P17861 3/20 0.43
ALOX15 P16050 3/20 0.43
C3AR1 Q16581 2/20 0.43
HSD17B10 Q99714 2/20 0.43
GAA P10253 1/20 0.43
KDM4E B2RXH2 4/20 0.41
HPGD P15428 4/20 0.41
CYP1A2 P05177 2/20 0.41
CYP3A4 P08684 2/20 0.41
CYP2D6 P10635 2/20 0.41
CYP2C9 P11712 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19319686 0.92 MAPT (0.47) MAPTKMT2AMEN1MAPK1NPSR1
SCHEMBL19319685 0.91 KMT2A (0.42) MAPTKMT2AMEN1MAPK1NPSR1
SCHEMBL4881203 0.83 MAPT (0.50) MAPTKMT2AMEN1MAPK1NPSR1
SCHEMBL19319698 0.82 MAPK1 (0.46) MAPTKMT2AMEN1MAPK1NPSR1
SCHEMBL24135990 0.81 KMT2A (0.36) MAPTKMT2AMEN1MAPK1NPSR1
SCHEMBL19319697 0.81 KMT2A (0.47) MAPTKMT2AMEN1MAPK1NPSR1
SCHEMBL19319684 0.81 NPSR1 (0.40) MAPTKMT2AMEN1MAPK1NPSR1
SCHEMBL19324990 0.80 MAOB (0.43) MAOBMAOA
SCHEMBL4884599 0.80 KMT2A (0.49) MAPTKMT2AMEN1MAPK1NPSR1
SCHEMBL4873458 0.79 MAPT (0.45) MAPTKMT2AMEN1MAPK1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3426636-B1 SPECIFIC 2-(4-(PHENOXY)-1H-PYRAZOL-3-YL)PHENOL DERIVATIVES AS INHIBITORS OF C-MYC/DNA BINDING ACTIVITY FOR TREATING CANCER UNIV NORTHWESTERN (US) 2021-12-29 EP disclosed
US-20210395206-A1 SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS NORTHWESTERN UNIVERSITY 2021-12-23 US disclosed
US-11142504-B2 Substituted heterocycles as c-MYC targeting agents NORTHWESTERN UNIVERSITY (US) 2021-10-12 US disclosed
WO-2020257261-A1 SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS NORTHWESTERN UNIVERSITY (US) 2020-12-24 WO disclosed
US-20200392116-A1 SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS NORTHWESTERN UNIVERSITY (US) 2020-12-17 US disclosed
WO-2020046382-A1 SUBSTITUTED HETEROCYCLES AS C-MYC TARGETING AGENTS NORTHWESTERN UNIVERSITY (US) 2020-03-05 WO disclosed
US-20170253581-A1 SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS NORTHWESTERN UNIVERSITY (US) 2017-09-07 US disclosed
US-20170253581-A1 SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS NORTHWESTERN UNIVERSITY (US) 2017-09-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200392116-A1 SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS MYC, MYCBP, MYCBP2 MAPT 3689/4885KMT2A 2062/4885MEN1 1497/4885
US-20210395206-A1 SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS MYC, MYCBP, MYCBP2 MAPT 3689/4885KMT2A 2062/4885MEN1 1497/4885
US-11142504-B2 Substituted heterocycles as c-MYC targeting agents MYC, MYCBP, MYCBP2 MAPT 3689/4885KMT2A 2062/4885MEN1 1497/4885
US-20170253581-A1 SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS MYC, MYCBP, MYCBP2 MAPT 3660/4885KMT2A 2069/4885MEN1 1590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.